Last reviewed: June 1, 2026 Last updated: June 1, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
(Top holdings, as of January 16, 2025, below): Source: Amplify ETFs The Roundhill GLP-1 & Weight Loss ETF (OZEM) is another ETF in this segment, also launched in May 2024
And as indicated by the list above of upcoming trials, there may be several new indications in the near future
Incretins Introduction Type 2 diabetes may result from a variety of conditions including -cell dysfunction, where insulin is not produced, and/or due to insulin resistance, in both cases leading to hyperglycemia, and complications in both small and large blood vessels (Silberstein, 2013)